Mylan announced that it has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Levalbuterol Inhalation Solution, the generic version of Sunovion’s Xopenex ...

Levalbuterol Inhalation Solution Teva has launched Levalbuterol Inhalation Solution, the generic version of Sunovion's Xopenex Inhalation Solution. Levalbuterol acts as a functional antagonist to ...

About one out of 12 people in the United States has asthma. Asthma is a chronic (long-term) lung condition in which airways ...

COPD - Chronic Obstructive Pulmonary Disease - including chronic bronchitis and emphysema, is characterized by breathing difficulty due to partial blockage of the bronchial tubes. Asthma is a chronic ...

This viewpoint offers commentary on important clinical research in the area of pharmacy. Investigations continue into this isomeric form of albuterol to determine its place in therapy. Many ...

Albuterol is a selective β 2-agonist that is widelyused in the prevention and treatment of reactive airwaydisease. It is formulated as a racemic mixturecontaining equal parts of the R- and ...

Development of levalbuterol was based on the following proposed advantages over racemic albuterol [3]: fewer episodes of transient tachycardia, better tolerability, and similar or greater efficacy. An ...

Co confirms that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Sepracor Inc. in connection with its Xopenex 0.31mg/3mL, 0.63mg/3mL and 1.25mg/3mL. On July ...